Steven R. Deitcher, MD, was appointed President and Chief Executive Officer and a member of the Board of Directors for Hana Biosciences in August 2007. Dr. Deitcher originally joined Hana as Executive Vice President of Development and Chief Medical Officer in May 2007. From 2004 until he joined Hana, Dr. Deitcher served as Vice President, Chief Medical Scientist at Nuvelo where he was responsible for clinical development and medical affairs. Dr. Deitcher has more than 15 years of experience as a practicing physician in hematology, medical oncology and vascular medicine. Dr. Deitcher was formerly the head of the section of hematology and coagulation medicine in the department of hematology/oncology and director of research in the department of vascular medicine at The Cleveland Clinic Foundation. While at The Cleveland Clinic, Dr. Deitcher was hematology medical director for the Network for Oncology Communication and Research. Prior to that, he spent four years at The University of Tennessee in positions including associate chairman, department of medicine; director, combined pediatric and adult thrombosis clinic; and director, special coagulation laboratory. Dr. Deitcher earned his B.S. and M.D. in the Honors Program in Medical Education at Northwestern University Medical School. He completed his residency in internal medicine at Barnes Hospital and completed his fellowship training in hematology and medical oncology at New England Medical Center and Tufts University School of Medicine. Dr. Deitcher is a member of several medical societies, including The American Society of Hematology, American Society of Clinical Oncology and the International Society on Thrombosis and Hemostasis, and is a fellow of the Society for Vascular Medicine and Biology. He has published more than 185 journal papers, abstracts and book chapters and has made more than 35 scientific conference presentations. He was the founding editor-in-chief of the journal Current Hematology Reports.
Howard Furst, MD, MBA, became a director at Hana in December 2009. Dr. Furst has over 20 years of experience in the healthcare industry and is currently a partner at Deerfield Management. He joined Deerfield Management in 2007 to work on structured transactions in Deerfield's Private Design and Special Situations Funds. Prior to joining Deerfield Management in 2007, Dr. Furst was a portfolio manager for the healthcare group at Magnetar Capital, an investment fund, from 2006 to 2007. Prior to joining Magnetar Capital, Dr. Furst was a principal at Maverick Capital, an investment firm, where he was primarily responsible for managing the firm's investments in the pharmaceutical and biotechnology sectors. Dr. Furst received his M.D. from the New York University School of Medicine, an M.B.A. with a dual concentration in finance and healthcare administration from the Wharton School of Business at the University of Pennsylvania, and a B.A. from the University of Pennsylvania. Dr. Furst also serves as a director of NitroMed, Inc., a privately-held specialty pharmaceutical company.
Paul V. Maier
Independent Financial Consultant
From 1992-2007, Mr. Maier served as Senior Vice President, Chief Financial Officer of Ligand Pharmaceuticals, Inc., a publicly-held biopharmaceutical company based in San Diego, CA. Prior to joining Ligand, Mr. Maier served as Vice President, Finance at DFS West, a division of DFS Group, L.P., a private multinational retailer. Previously, Mr. Maier held various positions in finance and administration at ICN Pharmaceuticals, Inc., a pharmaceutical and biotechnology research products company, and its subsidiary SPI Pharmaceuticals. Mr. Maier is currently an independent financial consultant and serves as a director on the boards of Pure Bioscience, Inc. and International Stem Cell Corp., both publicly-held companies. Mr. Maier received an M.B.A. from Harvard Business School and a B.S. from Pennsylvania State University.
Professor of Molecular Biology, Princeton University
Leon E. Rosenberg, M.D., a director of Hana since February 2004, has been a Professor in the Princeton University Department of Molecular Biology and the Woodrow Wilson School of Public and International Public Affairs since 1997. Since 1999, he has also been Professor Adjunct of Genetics at Yale University School of Medicine. From 1997 to 1998, Dr. Rosenberg served as Senior Vice President, Scientific Affairs of Bristol−Myers Squibb Company, and from 1991 to 1997, Dr. Rosenberg served as President of the Bristol−Myers Squibb Pharmaceutical Research Institute, where he was responsible for the company's worldwide pharmaceutical research and development. Prior to Bristol−Myers Squibb, Dr. Rosenberg was Dean of the Yale University School of Medicine from 1984 to 1991. Dr. Rosenberg also serves on the Boards of Directors of Lovelace Respiratory Research Institute (since 1997), Karo Bio AB (since 2000), and Medicines for Malaria Venture (since 2000).
Michael Weiser, M.D., Ph.D., has been a director at Hana since its inception. Dr. Weiser is currently founder and co-chairman of Actin Biomed, a New York based healthcare investment firm advancing the discovery and development of novel treatments for unmet medical needs. Prior to joining Actin Biomed, Dr. Weiser was the Director of Research at Paramount BioCapital where he was responsible for the scientific, medical and financial evaluation of biomedical technologies and pharmaceutical products under consideration for development. Dr. Weiser completed his Ph.D. in Molecular Neurobiology at Cornell University Medical College and received his M.D. from New York University School of Medicine. He performed his post-graduate medical training in the Department of Obstetrics and Gynecology at New York University Medical Center. Dr. Weiser also completed a Postdoctoral Fellowship in the Department of Physiology and Neuroscience at New York University School of Medicine and received his B.A. in Psychology from University of Vermont. Dr. Weiser is a member of The National Medical Honor Society, Alpha Omega Alpha, American Society of Clinical Oncology, American Society of Hematology and Association for Research in Vision and Ophthalmology. In addition, Dr. Weiser has received awards for both academic and professional excellence and is published extensively in both medical and scientific journals. Dr. Weiser currently serves on the board of directors of Chelsea Therapeutics International, Emisphere Technologies, Inc., Hana Biosciences, Inc., Manhattan Pharmaceuticals, Inc. and Ziopharm Oncology, Inc. as well as several privately held companies.
Lyn Wiesinger became a director at Hana in March 2007. Ms. Wiesinger is currently the principal of Strategic Decisions, a pharmaceutical consulting company. Ms. Wiesinger has more than 20 years of pharmaceutical operating experience in both global and US marketing, new product development, business acquisitions and licensing. Most recently, she was Senior Vice President of Marketing and Market Development at Vicuron Pharmaceuticals, a biotechnology company in the specialty hospital market, where she initiated and led the company's commercial function. She subsequently played an integral role in Vicuron's sale to Pfizer Inc. in September 2005. Prior to joining Vicuron, Ms. Wiesinger held senior positions at Bristol-Myers Squibb including Vice President, US Cardiovascular Marketing, where she lead the pre-launch program and marketing team for Vanlev, a novel antihypertensive and CHF treatment and Vice President, Global Marketing, Infectious Diseases , where she was responsible for managing the company's worldwide portfolio of antibiotics, antivirals and antifungals. Ms. Wiesinger established her early career in pharmaceuticals with an extensive tenure at Pfizer Inc., during which she held a broad range of management positions in new product development and marketing, marked by her leadership of the successful worldwide development and launch of Diflucan. Ms Wiesinger began her career as a consultant at Booz Allen and Hamilton. She holds an MBA degree from the Wharton School and a BA degree in psychology from the University of Pennsylvania. She is a member of the Board of Trustees of the National Foundation of Infectious Diseases, the Advisory Board of the Philadelphia University of the Sciences and a Director of the Wellness Community of Philadelphia.
show all
hide all
Member of the Finance & Transactions Committee
